A incidência de Candida albicans no exame de urina de homens e mulheres
DOI:
https://doi.org/10.34119/bjhrv7n9-460Keywords:
candida, problema, mortalidadeAbstract
A levedura Candida albicans tornou-se um importante problema de saúde pública, causando uma variedade de infecções, desde vaginais até profundas em pacientes hospitalizados, com altas taxas de morbidade e mortalidade. Embora seja um comensal comum do trato gastrointestinal e genital, pode se tornar patogênica sob certas condições, influenciada por fatores ambientais e interações com o sistema imunológico. Pacientes com AIDS e câncer são particularmente vulneráveis a infecções por C. albicans. Um dos principais fatores de virulência desta levedura é a formação de biofilmes, que conferem resistência a tratamentos antifúngicos. O tratamento padrão tem sido a anfotericina B, mas seus efeitos colaterais e custo elevado limitam seu uso. Antifúngicos azólicos são opções menos tóxicas, mas a resistência aos medicamentos tem aumentado, complicando o manejo das infecções.
References
ACHKAR JM, FRIES BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010 Apr;23(2):253-73.
ANDERSON TM, CLAY MC, CIOFFI AG, DIAZ KA, HISAO GS, TUTTLE MD, NIEUWKOOP AJ, COMELLAS G, MARYUM N, WANG S, UNO BE, WILDEMAN EL, GONEN T, RIENSTRA CM, BURKE MD. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014 May;10(5):400-6. doi: 10.1038/nchembio.1496. Epub 2014 Mar 30. PMID: 24681535; PMCID: PMC3992202.
BADIEE P, ALBORZI A, JOUKAR M. Ensaio molecular para detectar infecções fúngicas nosocomiais em unidades de terapia intensiva. Eur J Intern Med. 2011;22:611–615
BAYM M, STONE LK, KISHONY R. Multidrug evolutionary strategies to reverse antibiotic resistance. Science. 2016 Jan 1;351(6268):aad3292. doi: 10.1126/science.aad3292.
BIAGI, M.J.; WIEDERHOLD, N.P.; GIBAS, C.; WICKES, B.L.; LOZANO, V.; BLEASDALE, S.C.; DANZIGER, L. Development of high-level echinocandin resistance in a patient with recurrent candida auris candidemia secondary to chronic candiduria. Open Forum Infect. Dis. 2019, 6, ofz262.
BONGOMIN F, GAGO S, OLADELE RO, DENNING DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017 Oct 18;3(4):57.
BOUZA, E.; SAN JUAN, R.; MUÑOZ, P. 2001. A European perspective on nosocomial urinary tract infections II: report on incidence, clinical characteristics and outcome (ESGNI-004 study). Clinical Microbiology and Infection, v. 7, p. 532-542.
CALDERONE, R.; ODDS, F. C.; BOEKHOUT, T. Candida albicans: fundamental research on an opportunistic human pathogen. FEMS Yeast Research, v. 9, n. 7, p. 971–972, nov. 2009.
CONTI H.R, HUPPLER A.R, WHIBLEY N., GAFFEN S.L; Animal models for candidiasis. Curr Protoc Immunol. 2014 Apr 2;105:19.6.1-19.6.17.
CORTES L, JORGE A AND RUSSI N, JULY A. Echinocandins. Rev. chil. infectol. [online]. 2011, vol.28, n.6, pp.529-536.
COTTREAU JM, BARR VO. A Review of Antiviral and Antifungal Use and Safety during Pregnancy. Pharmacotherapy. 2016 Jun;36(6):668-78. doi: 10.1002/phar.1764. PMID: 27139037.
DANHOF, H. A., VYLKOVA, S., VESELY, E. M., FORD, A. E., GONZALEZ-GARAY, M., LORENZ, M. C. 2016. Robust Extracellular pH Modulation by Candida albicans during growth in carboxylic acids. mBio. 7, e01646-16.
ELLEPOLA AN, MORRISON CJ. Laboratory diagnosis of invasive candidiasis. J Microbiol. 2005 Feb;43 Spec No:65-84. PMID: 15765060.
ESMAILZADEH A, ZARRINFAR H, FATA A. 2018. High prevalence of candiduria due to non-albicans Candida species among diabetic patients: a matter of concern? J Clin Lab Anal 32:e22343
FELTON T, TROKE PF, HOPE WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13.
FISHER JF. Candida urinary tract infections – epidemiology, pathogenesis, diagnosis and treatment: executive summary. Clin. Infect. Dis.52(Suppl. 6), S429–S432 (2011).
FISHER JF, KAVANAGH K, SOBEL JD, KAUFFMAN CA, NEWMAN CA. Candida urinary tract infection: pathogenesis. Clin Infect Dis. 2011 May;52 Suppl 6:S437-51. doi: 10.1093/cid/cir110. PMID: 21498837.
GAO Y, CAO Q, XIAO Y, WU Y, DING L, HUANG H, LI Y, YANG J, MENG L. The progress and future of the treatment of Candida albicans infections based on nanotechnology. J Nanobiotechnology. 2024 Sep 16;22(1):568.
GRIFFITH N, DANZIGER L. Candida auris Urinary Tract Infections and Possible Treatment. Antibiotics (Basel). 2020 Dec 12;9(12):898. doi: 10.3390/antibiotics9120898. PMID: 33322761; PMCID: PMC7764735.
HELBIG S, ACHKAR JM, JAIN N, WANG X, GIALANELLA P, LEVI M, FRIES BC. Diagnosis and inflammatory response of patients with candiduria. Mycoses. 2013 Jan;56(1):61-9. doi: 10.1111/j.1439-0507.2012.02201.x. Epub 2012 May 10. PMID: 22574854; PMCID: PMC3419311.
HILL, J.A., AMMAR, R., TORTI, D., NISLOW, C., COWEN, L.E. 2013. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet. 9, e1003390.
KASHEM, S. W., IGYÁRTÓ, B. Z., GERAMI-NEJAD, M., KUMAMOTO, Y., MOHAMMED, J., JARRETT, E., DRUMMOND, R. A., ZURAWSKI, S. M., ZURAWSKI, G., BERMAN, J. 2015. Candida albicans morphology and dendritic cell subsets determine T helper cell differentiation. Immunity 42, 356- 366.
KAUFMAN CA. (2014). Diagnosis and Management of Fungal Urinary Tract Infection. Infect Dis Clin North Am 28:61–74
KETT DH, AZOULAY E, ECHEVERRIA PM, VINCENT JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39:665–70.
KIM, J., SUDBERY, P. 2011. Candida albicans, a major human fungal pathogen. J Microbiol. 49, 171.
LEE Y, PUUMALA E, ROBBINS N, COWEN LE. Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. Chem Rev. 2021 Mar 24;121(6):3390-3411. doi: 10.1021/acs.chemrev.0c00199. Epub 2020 May 22. PMID: 32441527; PMCID: PMC8519031.
LOSSE J, ZIPFEL PF, JÓZSI M. Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J Immunol 2010; 184(2):912-21; PMID:20008295.
MARAK MB, DHANASHREE B. Antifungal Susceptibility and Biofilm Production of Candida spp. Isolated from Clinical Samples. Int J Microbiol. 2018 Oct 10;2018:7495218. doi: 10.1155/2018/7495218. PMID: 30405717; PMCID: PMC6199855.
MAYER, F.L., WILSON, D., HUBE , B. 2013. Candida albicans pathogenicty mechanisms. Virulence 4, 119-128.
PADAWER D, PASTUKH N, NITZAN O, LABAY K, AHARON I, BRODSKY D, GLYATMAN T, PERETZ A. Catheter-associated candiduria: Risk factors, medical interventions, and antifungal susceptibility. Am J Infect Control. 2015 Jul 1;43(7):e19-22.
POULAIN, D. Candida albicans, plasticity and pathogenesis. Critical Reviews in Microbiology, v. 41, n. 2, p. 208–217, 20 ago. 2013.
PRAZ V, BURRUNI R, MEID F. 2014. Fungus ball in the urinary tract: a rare entity. Can Urol Assoc J 8:E118–E120
RAPALA‐KOZIK, M., BOCHENSKA, O., ZAJAC, D., KARKOWSKA‐KULETA, J., GOGOL, M., ZAWROTNIAK, M., KOZIK, A. (2018). Proteinases extracelulares de leveduras patogênicas de espécies de Candida . Molecular Oral Microbiology, 33(2), 113–124.
RAI LS, WIJLICK LV, BOUGNOUX ME, BACHELLIER-BASSI S, D'ENFERT C. Regulators of commensal and pathogenic life-styles of an opportunistic fungus-Candida albicans. Yeast. 2021 Apr;38(4):243-250. doi: 10.1002/yea.3550. Epub 2021 Feb 23. PMID: 33533498.
REBOLI AC, ROTSTEIN C, PAPPAS PG, CHAPMAN SW, KETT DH, KUMAR D, BETTS R, WIBLE M, GOLDSTEIN BP, SCHRANZ J, KRAUSE DS, WALSH TJ; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 Jun 14;356(24):2472-82.
REBOLI AC, SHORR AF, ROTSTEIN C, PAPPAS PG, KETT DH, SCHLAMM HT, REISMAN AL, BISWAS P, WALSH TJ. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011 Sep 30;11:261.
RAJENDRAN R, MAY A, SHERRY L, KEAN R, WILLIAMS C, JONES BL, BURGESS KV, HERINGA J, ABELN S, BRANDT BW, MUNRO CA, RAMAGE G. Integrating Candida albicans metabolism with biofilm heterogeneity by transcriptome mapping. Sci Rep. 2016 Oct 21;6:35436.
ROBBINS N, CAPLAN T, COWEN LE. Molecular Evolution of Antifungal Drug Resistance. Annu Rev Microbiol. 2017 Sep 8;71:753-775. doi: 10.1146/annurev-micro-030117-020345. PMID: 28886681.
SAMPAIO, R.F; MANCINI, M.C; Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Revista Brasileira de Fisioterapia. São Carlos, v. 11, n.1, p.83-89, jan./fev. 2007.
SENET JM. Candida adherence phenomena, from commensalism to pathogenicity. Int Microbiol. 1998 Jun;1(2):117-22. PMID: 10943349.
SOBEL JD. Vulvovaginal candidosis. Lancet. 2007 Jun 9;369(9577):1961-71. doi: 10.1016/S0140-6736(07)60917-9. PMID: 17560449.
SPITZER, M.; ROBBINS, N.; WRIGHT, G. D. Combinatorial Strategies for Combating Invasive Fungal Infections. Virulence 2017, 8, 169−185.
STEINBACH WJ. Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children. J Fungi (Basel). 2016 Jan 8;2(1):5. doi: 10.3390/jof2010005. PMID: 29376923; PMCID: PMC5753086.
THOMAS L. TRACY CR; (2015) Treatment of fungal urinary tract infection. Urol Clin North Am 42:473–483
VERMA‐GAUR, J., TRAVEN, A. 2016. Post‐transcriptional gene regulation in the biology and virulence of Candida albicans. Cell. Microbiol. 18, 800-806.]
VOLTAN, A.R; FUSCO-ALMEIDA, A.M; MENDES-GIANNINI, M.J.S. Candiduria: epidemiology, resistance, classical and alternative antifungal drugs. Symbiosis, 2014.
VYLKOVA S. Environmental pH modulation by pathogenic fungi as a strategy to conquer the host. PLoS Pathog. 2017 Feb 23;13(2):e1006149.
WANG K, HSUEH K, KRONEN R. 2019. Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria. Mycoses 62:554–561.
WILSON, D., NAGLIK, J. R., HUBE, B. 2016. The Missing Link between Candida albicans Hyphal Morphogenesis and Host Cell Damage. PLoS Pathog. 12, e1005867.
